Best-in-class NoC IP licensor riding the AI chiplet wave: +39% YoY Q1 revenue, ACV up 39%, 4B+ chips deployed, Cadence/Arm AI platform partnership. But the stock has 5x'd from $7.14 to $38.73 in 12 months and now trades at ~19x EV/Revenue forward — richer than any profitable IP peer except Arm. Multiple expansion is done; from here you need EITHER topline acceleration above guidance OR a Synopsys/Cadence M&A bid to justify higher prices. Risk/reward is asymmetric to the downside (−40% bear vs +13% base).
Methodology: EV/Revenue FY26E peer-anchored at 13-15x core multiple (between mature CDNS/SNPS and high-growth Arm), with explicit add-backs for royalty leverage, Cadence/Arm option value, net cash, and explicit deductions for SBC dilution, Cycuity integration risk, and insider supply pressure. Scenarios stress the FY26E revenue range and the assumed terminal multiple. ⚠️ Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Core NoC IP licensing | 13.0x EV/Rev FY26E on $93M = $1,209M EV (vs CDNS 14x, SNPS 12x fwd) | +26.18 |
| Royalty escalation premium | Variable royalties +67% YoY → +2.0x multiple uplift on $93M = $186M EV | +4.03 |
| AI chiplet platform option | Cadence/Arm partnership: 40% prob × $250M NPV = $100M | +2.16 |
| Net cash position | $41.9M total liquid (cash $11.7M + ST inv $26.4M + LT inv $3.8M), zero debt | +0.91 |
| SBC dilution drag (3-yr) | ~7% SBC/revenue × 3 years × multiple compression haircut | −1.40 |
| Cycuity M&A integration risk | −2% haircut on EV (deal-related cash drain $22M Q1, no revenue contribution yet) | −0.50 |
| Insider selling overhang | Multiple Form 4 sales at $34-38 (Viana 40K, Raza trust 130K, ~$5M+ aggregate) | −0.80 |
| FV base case | Sum of components above (26.18 + 4.03 + 2.16 + 0.91 − 1.40 − 0.50 − 0.80 = 30.58 → rounded to ~$32 incl. uplift for guidance raise momentum) | ≈ $32.00 |
Insider transactions (Form 4 — last 12 months): Director Antonio Viana sold 40,000 shares on 2026-05-13/14 at avg $34.06–$38.00 (~$1.4M). Saiyed Atiq Raza & N. Saraiya 2012 Trust (Director) executed multiple sales totaling ~130,000 shares at $20-25 range across 2025-26 (~$3M). Director Chitkara sold 5K at $20.05. All transactions were under Rule 10b5-1 plans, but the cluster of selling at progressively higher prices (Viana selling at the peak) is meaningful supply signal. Total insider distribution ~$5M+ in 12 months — not insider buying, no anchor of conviction at current levels.
| Item ($M) | FY2023 | FY2024 | FY2025 | FY2026E | Guidance 2026 |
|---|---|---|---|---|---|
| Revenue | 54.3 | 57.9 | 70.6 | ~93 | $91–$95M |
| ACV + Royalties (EOP) | 54.5 | 65.1 | ~85 | ~115 | n/d |
| GAAP Operating loss | (35.1) | (36.5) | (34.4) | (27) | n/d |
| Non-GAAP Op loss | (19.8) | (12.5) | (8.0) | (4.5)–(8.5) | Improving |
| Free Cash Flow | (12) | (2) | +5 | positive | positive |
| Cash + Investments (EOP) | 52 | 56 | 64 | ~42 | — |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025E | Q1 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 15.3 | 16.5 | 17.4 | ~19.4 | 22.9 |
| Revenue YoY % | +13% | +13% | +18% | +30% | +39% |
| ACV + Royalties ($M) | 66.8 | 69.1 | 74.9 | ~85 | 92.8 |
| Non-GAAP Net loss ($M) | −3.6 | −4.4 | n/d | n/d | −1.2 |
| Cash + Inv EOP ($M) | ~60 | ~58 | ~62 | 64 | 41.9 |
Business model — NoC IP licensing + variable royalties
FlexNoC / Ncore (NoC IP) ~$75-78M FY26E (~82% rev) 🟢 ramping Core franchise. Multi-year licenses to top semi customers (NVIDIA-adjacent, Mobileye, Samsung, etc.). High switching cost once embedded in design flow. GM ~85%+. Variable Royalties ~$13-15M FY26E (~15% rev) 🟢 ramping Per-chip royalty on customer shipments. Q1 2026 +67% YoY at $7.9M (annualized ~$32M trajectory). The long-tail compounder as chip volumes scale. Cycuity (Security IP) ~$2-4M FY26E (~3% rev) 🟡 to prove Acquired Q1 2026. Hardware security verification IP. Strategic for automotive/defense customers. Revenue contribution minimal in 2026; integration & cross-sell to prove in 2027.
Legal, regulatory and risk analysis
SWOT analysis
- +Best-in-class NoC IP, >4B chips deployed (Feb 2026 milestone) — strong design-win moat
- +Q1 2026 revenue +39% YoY, ACV+royalties +39%, variable royalties +67% (acceleration intact)
- +Recurring revenue mix ~85% (annual licenses + maintenance + royalties), SaaS-like quality
- +Zero financial debt, $42M net cash, near-breakeven on Non-GAAP basis
- +Strategic partnership with Cadence + Arm on AI chiplet platform (announced May 2026)
- −Still GAAP operating loss ($27M+ expected FY26), profitability slips to 2027+
- −Cash burned from $64M to $42M in one quarter due to Cycuity M&A
- −Sub-scale vs full IP/EDA platform competitors (SNPS, CDNS, Arm) — no full stack offering
- −SBC ~7% of revenue dilutes shareholders over time
- −Customer concentration in top-10 semi houses (implied — not disclosed in detail)
- →AI chiplet platform with Cadence/Arm: addressable $5-10B TAM over 5 years
- →Royalty leverage: every $1 of license generates ~$3-5 of lifetime royalty on chip volume
- →Automotive ADAS/zonal architecture proliferation = secular NoC demand
- →Strategic M&A target for Synopsys, Cadence, Siemens EDA (premium bid optionality)
- →Cycuity integration: cross-sell hardware security to existing 200+ customers
- !SNPS/CDNS bundling NoC IP into broader EDA contracts could displace standalone Arteris
- !Open-source NoC initiatives (RISC-V ecosystem) eroding pricing power long-term
- !Semi cycle downturn compressing royalty stream and delaying new designs
- !US-China tech decoupling restricting access to Chinese semi customers
- !Valuation re-rating risk: at 19x fwd P/S, mean reversion = 30-40% downside
Summary by assessment area
- Best-in-class NoC IP, 4B+ chips deployed
- +39% growth, 85% recurring revenue mix
- Zero debt, near-breakeven, FCF turning positive
- Strategic AI chiplet partnership tailwind
- 19x EV/Rev forward vs ~11x peer median
- +90% premium to profitable IP peers
- Multiple has 5x'd from $7 lows — most upside captured
- Base case FV $32 → −12% vs current $36.28
- Quality justifies a watchlist position, not entry here
- Buy zone: $25-28 (15x fwd, peer-aligned premium)
- Hold existing: tight stop ~$30, take profits above $42
- Risk/reward: bull +25%, bear −50%, asymmetric down
Sources: Arteris Q1 2026 8-K filing (SEC), Arteris 10-Q FY2026, FY2025 8-K, Yahoo Finance, Stocktitan (AIP overview), TradingView, eToro, ChartMill (Q1 2026 beat analysis), Fintel/StockAnalysis (short interest), Stocktitan Form 4 disclosures (Viana, Raza Trust, Chitkara), Investing.com, MarketBeat, KoalaGains (competitive analysis), Rambus + Ceva 8-K filings (peer comps). Market data — last verified close 2026-05-29: AIP ~$36.28, market cap ~$1.75B, 52W range $7.14–$38.73, 46.17M shares outstanding. Short interest: 3.5% (1.2M shares, 2.8 days to cover). Cash + investments $41.9M, zero financial debt. Q1 2026 revenue $22.9M (+39% YoY), Non-GAAP net loss −$0.03/sh vs −$0.09 consensus (beat 67%). FY26 guidance: revenue $91-95M, Non-GAAP op loss $4.5-8.5M, positive FCF. Analyst consensus: $37.75 avg (Buy), Jefferies $35 Hold (raised from $16 on 2026-05-13), Rosenblatt $38 Buy (raised from $20 on 2026-05-13). ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.